Guidance on the Safe Supply of Dovonex® Psoriasis Ointment by Pharmacists

The purpose of this guidance is to assist pharmacists in the safe supply of Dovonex® Psoriasis ointment, in line with the product’s marketing authorisation.

Guidance on the Safe Supply of Dovonex® Psoriasis Ointment by Pharmacists pdf cover

In this guidance we highlight key points that should be considered by pharmacists in ensuring the safe supply of Dovonex® Psoriasis (calcipotriol 50 microgram/g) ointment.  This product is licensed as a pharmacy only medicine for the treatment of adults with mild to moderate plaque psoriasis which has been previously diagnosed by a doctor.  

Due to the need to confirm the patient’s diagnosis of plaque psoriasis and the counselling requirements for the appropriate use of this product, Dovonex® Psoriasis ointment must only be supplied by the pharmacist. 

The product’s Summary of Product Characteristics (SmPC) and Package Leaflet are available are available to view on the HPRA website. 

A training deck on this product for pharmacists is available on request by email to LEO Pharma medical information.